10x Genomics Collaborates With Charité And Seoul National University On Identifying Blood-Based Biomarkers Of Disease Activity And Treatment Response For Autoimmune Disease
Benzinga Newsdesk 16 hours ago
News
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platformPLEASANTON, Calif., Nov. 16, 2026
Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platform
PLEASANTON, Calif., Nov. 16, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced two new research collaborations focused on identifying blood-based biomarkers of disease activity and treatment response for autoimmune disease. The first collaboration is with Charité – Universitätsmedizin Berlin, one of Europe's largest university hospitals, and the German Rheumatology Research Center Berlin (DRFZ). The second is with the Genomic Medicine Institute at Seoul National University (SNU), one of South Korea's leading research universities.
